<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="UTF-8">
  <title>Proper 2 - About the study</title>
  <link rel="preconnect" href="https://fonts.gstatic.com">
  <link
    href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;1,300;1,400;1,600;1,700&display=swap"
    rel="stylesheet">
  <link rel="stylesheet" href="style.css" />
  <link rel="icon" href="favicon.ico" />
</head>

<body>
  <header>
    <div>
      <a href="index.html"><img src="images/proper2.svg" alt="" width="291" height="74" /></a>
      <h1a>The PSA-Rec-Predicator</h1a>
      <nav>
        <img src="images/ham_nav.svg" alt="" />
        <ul>
          <li><a href="index.html">Home</a></li>
          <li><a href="about.html">About the study</a></li>
          <li><a href="faq.html">FAQ</a></li>
          <li><a href="contact.html">Contact</a></li>
        </ul>
      </nav>
    </div>
    <p2>
      This calculator is used to calculate the risk of a new prostate cancer
      recurrence within three years to select patients for randomization
      between receiving an addition of pelvic lymph node irradiation or not.
      <a href="about.html">read more &raquo;</a>
    </p2>
    <hr>
  </header>
  <main>
    <h1>About the study</h1>
    <p>The PSA-Rec-Predictor displayed on this homepage has been developed by the PROPER study group through prospective
      clinical trials on patients with biochemical recurrence treated with salvage radiotherapy (REFS). </p>
    <p>The results from these studies demonstrated that the risk of a new prostate cancer recurrence after salvage
      radiotherapy (SRT) can be predicted with high accuracy. This was done by including PSA decay (as a PSA decay-rate
      constant (k)) during radiotherapy and selected prognostic clinical factors in a prediction model. These parameters
      are included in The PSA-Rec-Predictor. </p>
    <p>The PSA decay-rate constant (kPSA) is calculated by using linear regression of ln(PSA) vs time assuming first
      order kinetics. This calculator is used in the prospective randomized phase III trial called PROPER 2 to calculate
      the risk of a new prostate cancer recurrence within three years to select patients for randomization between
      receiving an addition of pelvic lymph node irradiation or not. </p>
    <p>For further information on the study please find it on clinicaltrials.gov (ref. number to be added). </p>
    <h1>About the PROPER study group</h1>
    <p>Consectetur adipiscing elit. Integer sed odio
      maximus, efficitur ante vel, imperdiet augue. Suspendisse mi ligula,
      interdum vel egestas at, rhoncus ac nibh. Quisque gravida metus eget justo
      tempor, ut consectetur urna tincidunt. Vestibulum ipsum turpis, facilisis
      ut nisl ac, aliquam euismod felis. Nulla elementum ante ut varius
      sagittis.
      In hac habitasse platea dictumst. Fusce eget velit nec ligula
      bibendum rutrum. In ac justo et leo tempor rutrum. Morbi interdum
      elementum diam sed malesuada. Suspendisse dapibus consequat ultricies.
      Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere
      cubilia curae; Ut magna nisl, feugiat sed egestas ac, pretium ut ligula.
      Maecenas feugiat in justo id viverra. Fusce ac vestibulum enim, at
      molestie nunc.
      Curabitur eget ullamcorper erat. Sed nibh urna, tincidunt
      in nisi imperdiet, viverra volutpat quam. Integer elit risus, mattis eget
      dignissim eu, porta quis turpis. Nulla sodales, ex quis ornare dapibus,
      metus tellus tristique nulla, in gravida mi mi id arcu. Morbi enim ligula,
      convallis faucibus placerat vitae, aliquet eget velit. Duis in euismod
      orci.
      Suspendisse viverra tortor urna, sit amet viverra urna fermentum
      eget. Mauris eleifend nisi vel arcu tempus, eget convallis sapien
      ultricies. Fusce odio.</p>
  </main>
  <footer>
    <a href="index.html"><img src="images/Proper2_small_white.svg" alt="" width="116" height="30" /></a>
    <ul>
      <li><a href="about.html">About the study</a></li>
      <li><a href="faq.html">FAQ</a></li>
      <li><a href="contact.html">Contact</a></li>
    </ul>
  </footer>
</body>

</html>